David Sinclair and NMN: What He Takes, What the Science Actually Says

Written by the Nuvirox Research Team

Short answer: Sinclair's NMN protocol is real, but it is his own experiment, not a prescription for everyone. David Sinclair, a professor of genetics at Harvard Medical School, has publicly described taking 1 gram (1,000 mg) of NMN each morning — usually alongside resveratrol and yogurt. That disclosure turned NMN from an obscure biochemistry term into one of the most-searched supplement ingredients in the longevity space. But there is a gap between what Sinclair does and what the peer-reviewed evidence recommends, and closing that gap is what this article is about.

Who is David Sinclair and why does his NMN stack matter?

Sinclair is the co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School and the author of Lifespan: Why We Age — and Why We Don't Have To. His research focuses on epigenetic reprogramming, sirtuin biology, and NAD+ metabolism — which is to say, he works on the exact pathways that NMN is hypothesized to influence. His personal protocol, compiled from podcast interviews and public statements over several years, includes 1 g NMN, 1 g resveratrol, metformin (800 mg, a prescription drug), vitamin D3, vitamin K2, and other compounds.

Sinclair has consistently stated he prefers NMN over nicotinamide riboside (NR) because NMN sits one step closer to NAD+ in the biosynthesis pathway — it converts to NAD+ without requiring phosphorylation first. He has cited unpublished mouse data showing improved exercise performance with NMN vs. NR. It is worth noting, however, that he does not endorse any specific brand, his protocol reflects a higher tolerance for uncertainty than would be appropriate for most supplement users, and his access to advanced biomarker monitoring is not typical of consumer supplementation.

Simplified illustration of NAD+ salvage biosynthesis. NMN bypasses the rate-limiting NAMPT step when taken as a supplement. Pathway is illustrative, not drawn to biochemical scale.

What does NMN actually do in the body?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell that participates in hundreds of metabolic reactions — from extracting energy from glucose to enabling DNA repair via enzymes called PARPs and sirtuins. NAD+ levels decline measurably with age, and this decline is thought to contribute to reduced mitochondrial efficiency, impaired DNA repair capacity, and the general physiological slowdown associated with aging.

NMN is a direct precursor to NAD+. When taken orally, NMN enters cells and is converted to NAD+ by an enzyme called NMNAT, bypassing the rate-limiting NAMPT step in the salvage pathway. This is the biochemical basis for Sinclair's preference for NMN over plain nicotinamide (NAM), which must travel through NAMPT before becoming NMN. Whether this theoretical advantage translates to meaningfully higher NAD+ levels in humans — compared to other precursors like NR — is a question the clinical literature is actively working through. A 2026 head-to-head randomized study published in Nature Metabolism found that NR and NMN raised circulatory NAD+ comparably over 14 days, while plain NAM did not produce significant increases at the doses studied. You can read more about this comparison in our article on NR vs. NMN vs. NAD+ precursors.

What do human studies on NMN actually show?

The Yi et al. (2022) dose-finding trial is among the most comprehensive NMN human RCTs published. In this randomized, multicenter, double-blind, placebo-controlled parallel-group study (n = 80 healthy middle-aged adults), participants received placebo, 300 mg, 600 mg, or 900 mg NMN daily for 60 days. All three NMN doses significantly increased blood NAD+ levels compared to placebo, in a dose-dependent fashion. The 600 mg and 900 mg doses produced significantly higher NAD+ than 300 mg. Participants receiving NMN also walked further on a 6-minute walk test and reported improvements in self-assessed health perception. The authors concluded that doses of 300–900 mg/day are safe and effective at raising NAD+. (Yi L et al., Geroscience, 2022; PMID: 36482258.)

The Okabe et al. (2022) safety trial — a randomized, double-blind, placebo-controlled parallel-group study from Japan (n = 30 healthy adults, 250 mg/day NMN for 12 weeks) — found no abnormalities in physiological or laboratory parameters and no adverse effects. Whole-blood NAD+ rose significantly in the NMN group. (Okabe K et al., Frontiers in Nutrition, 2022; doi: 10.3389/fnut.2022.868640.)

A 2024 systematic review and meta-analysis (Zhang J et al., Critical Reviews in Food Science and Nutrition, 2024; doi: 10.1080/10408398.2024.2387324) pooled data from 9 NMN studies including 412 participants. The review found NMN significantly increased blood NAD+ levels overall. For functional outcomes, NMN had significant effects on muscle mass (SMD 0.34 m/s in gait speed, 95% CI 0.03–0.66) and reduced insulin resistance at lower doses, while effects on lipid levels were inconsistent. The honest read from this review is that NMN's ability to raise NAD+ is well-supported; its downstream clinical effects are real in some domains but not uniformly demonstrated across all metabolic endpoints.

The null finding worth knowing about: A 2023 randomized trial in Scientific Reports (n = 36 middle-aged adults, 250 mg/day NMN for 12 weeks) found that while serum nicotinamide levels increased significantly in the NMN group, pulse wave velocity — a marker of arterial stiffness — only trended toward improvement without reaching statistical significance. This underscores a recurring theme in the NMN literature: NAD+ goes up reliably, but which clinical endpoints follow is not yet predictable.

Sinclair takes 1,000 mg. Should you?

Sinclair's 1 g daily dose sits at the higher end of what human trials have used. Published trials have generally employed doses between 250 mg and 900 mg/day, with the most comprehensive dose-finding work suggesting meaningful NAD+ elevation begins around 300–600 mg. Sinclair's 1 g choice appears to be based partly on his reading of preliminary mouse studies showing a dose-response relationship for exercise performance — data that, by his own account, were not published at the time he disclosed them.

For most people starting NMN supplementation, the evidence base supports starting at 250–500 mg/day to assess tolerance, then adjusting based on individual response. The 1 g dose used by Sinclair is not contraindicated by available safety data, but it is not the dose most human trials have confirmed as a minimum effective dose. Sinclair has also consistently noted that his protocol reflects his personal risk tolerance and access to medical monitoring — circumstances that differ from the average supplement user.

What NMN won't do

NMN is not a longevity drug with proven effects on human lifespan — that data does not exist yet. The dramatic results seen in mouse studies (reversal of vascular aging, improved fertility, restored muscle function) have not been replicated in human trials, which are shorter, less controlled, and more heterogeneous. NMN also will not compensate for chronically poor sleep, sedentary behavior, or unaddressed metabolic disease. If fatigue or cognitive decline is your concern, these symptoms have many possible causes — thyroid dysfunction, sleep apnea, iron deficiency, and mood disorders among them — and evaluating those causes with a physician is the appropriate first step before adding any supplement. Sinclair himself takes NMN as part of a comprehensive health protocol that includes rigorous exercise and sleep hygiene; the supplement is not the whole story even by his own account.

There is also an important regulatory update worth knowing: from late 2022 through most of 2025, NMN's legal status as a dietary supplement in the U.S. was contested, after the FDA cited a drug preclusion clause. That dispute was resolved in September 2025, when the FDA reversed course and confirmed that NMN is not excluded from the definition of a dietary supplement. NMN is now legally marketed as a supplement in the U.S. under normal DSHEA rules, provided manufacturers meet New Dietary Ingredient notification requirements. For more background on the legal and evidence history of NMN, see our full article on Nicotinamide Mononucleotide: Evidence, Safety, and the FDA Saga.

What users report

Forum discussions across Reddit communities focused on biohacking and longevity supplementation tend to reflect a consistent pattern: users report subjective improvements in energy and mental clarity within the first few weeks, often at doses between 250 mg and 500 mg. Some report diminishing returns or no noticeable effect at 500 mg and increase to 1 g, citing Sinclair's protocol as their reference. A subset of users report mild nausea at higher doses, which often resolves with food. There is a meaningful vocal cohort who tried NMN for 3–6 months, noticed nothing subjective, and stopped. This is consistent with the trial data: NAD+ goes up in blood tests for most people, but whether that translates to a felt difference varies considerably among individuals. As with all anecdotal self-reports, these observations cannot establish causation and are offered here strictly as context for what people are asking when they search this topic.

Frequently asked questions

Does David Sinclair still take NMN in 2026?
Based on his most recent public interviews and podcast appearances through early 2026, Sinclair has continued describing NMN as part of his daily protocol. His specific formulation or dose may evolve as new research emerges. He has acknowledged that his stack is not static and that he adjusts based on new data.

Why does Sinclair take NMN with resveratrol?
Sinclair's hypothesis is that resveratrol activates sirtuins — particularly SIRT1 — and that sirtuins require NAD+ as a co-substrate to function. The theoretical logic is that more NAD+ (from NMN) gives resveratrol-activated sirtuins more fuel to work with. The clinical evidence for this synergy in humans is limited, and resveratrol's own bioavailability and efficacy in humans remain debated. Sinclair takes resveratrol with fat (typically yogurt) to improve absorption. Our article on NAD+ and Resveratrol: Do They Actually Work Together? covers that evidence specifically.

Is the 1,000 mg dose Sinclair takes safe?
Human trials have not reported serious adverse events at doses up to 900 mg/day for up to 60 days. One 12-week trial at 250 mg/day found no laboratory or physiological abnormalities. No long-term safety data in humans exists beyond these study durations. The 1 g dose has not been formally evaluated in a controlled trial; it is extrapolated from animal data and Sinclair's personal experimentation. Current evidence suggests 250–600 mg/day as the better-studied range for most adults.

Should I take NMN in the morning like Sinclair does?
Sinclair takes NMN in the morning based on a hypothesis about alignment with circadian rhythms and NAD+ cycling. Human trials have not directly compared morning versus evening dosing for NMN. Morning dosing is reasonable and may help with consistency, but the clinical data does not strongly favor a particular time of day at this stage.

Does NMN require a prescription in the U.S.?
No. As of September 2025, the FDA confirmed that NMN is lawful for use as a dietary supplement in the U.S. No prescription is required. Normal supplement regulations under DSHEA apply.

The bottom line

David Sinclair has done more than any single researcher to bring NMN into public conversation — and for good reason. The underlying biology is solid: NAD+ declines with age, NMN reliably raises it in human trials, and the relevant pathways are deeply connected to cellular energy and repair. Where Sinclair's protocol and the clinical evidence diverge is primarily on dose and certainty. His 1 g/day habit is personal, not prescriptive. The human trial evidence most consistently supports 300–600 mg/day as an effective range for NAD+ elevation, with some functional benefits reported in walking speed, insulin sensitivity, and self-assessed wellbeing. The long-term outcome data — the stuff that would tell you whether raised NAD+ translates to genuinely longer, healthier human life — is still being gathered. That honest caveat is not a reason to dismiss NMN; it is the reason to approach it as a supplement with real science behind it, rather than a certainty.

---

References

1. Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2022 Dec 8. doi: 10.1007/s11357-022-00705-1. PMID: 36482258.
2. Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640. doi: 10.3389/fnut.2022.868640.
3. Zhang J, Poon ETC, Wong SHS. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Crit Rev Food Sci Nutr. 2025;65(22):4382–4400. doi: 10.1080/10408398.2024.2387324. PMID: 39116016.
4. Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging. 2022;8:5.
5. Chellappa K, McReynolds MR, Lu W, et al. NAD precursors cycle between host tissues and the gut microbiome. Cell Metab. 2022;34(12):1947–1959.e5. doi: 10.1016/j.cmet.2022.11.004. PMID: 36476934; PMCID: PMC9825113.
6. Natural Products Association. FDA Reinstates NMN as Dietary Supplement After NPA Lawsuit. December 2025. Available at: npanational.org.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.